Gabelli Funds’s Relay Therapeutics RLAY Stock Holding History

Gabelli Funds’s Portfolio RLAY Stock Details RLAY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$187K	Sell	10,000 -2,000	-17%	-$29K	﹤0.01%	1184
2026 Q1	$119K	Buy	+12,000	New	+$107K	﹤0.01%	1177

Other funds holding RLAY

SIAU

SB Investment Advisers (UK) London, United Kingdom $7.66B AUM 20.12% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return

Gabelli Funds's RLAY Position: Q2 2026 in Review

Gabelli Funds reduced its Relay Therapeutics (RLAY) stake by 17% in Q2 2026, selling an estimated $29K and leaving 10,000 shares worth $187K. The position accounts for ﹤0.01% of the portfolio, ranked #1184.

Gabelli Funds first reported a position in RLAY in Q1 2026 and has held it in 2 quarters since. 260 funds tracked by Wall St. Rank hold RLAY as of Q2 2026.

Gabelli Funds held 10,000 shares of Relay Therapeutics worth $187K as of Q2 2026.
Gabelli Funds sold 2,000 Relay Therapeutics shares in Q2 2026, an estimated $29K.
Relay Therapeutics made up ﹤0.01% of Gabelli Funds's portfolio in Q2 2026, its #1184 holding.
Gabelli Funds first reported a position in Relay Therapeutics in Q1 2026 and has held it in 2 quarters since.
260 funds tracked by Wall St. Rank held Relay Therapeutics as of Q2 2026.

Based on Gabelli Funds's 13F filing for Q2 2026, filed 12 Aug 2026.